Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4130 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Genovate Biotechnology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovate Biotechnology Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Genovate Biotechnology Co's Days Payable falls into.
Genovate Biotechnology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Genovate Biotechnology Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovate Biotechnology Co (ROCO:4130) has a Days Payable of 36.37 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genovate Biotechnology Co and its competitors. This is 21% below median its historical median of 46.26. Over the past decade, Genovate Biotechnology Co's Days Payable has ranged from 37.28 to 54.25. According to the industry distribution chart, Genovate Biotechnology Co ranks #521 out of 701 companies in the Biotechnology industry, placing it in the top 74.3%.
Is Genovate Biotechnology Co's Days Payable too high?
Genovate Biotechnology Co's current Days Payable of 36.37 is 21% below median its 10-year median of 46.26. Over the past 10 years, this metric has ranged from a low of 37.28 to a high of 54.25. The Biotechnology industry median Days Payable is 112.84. Genovate Biotechnology Co's value of 36.37 is 67.8% below this industry median. Based on the distribution chart, Genovate Biotechnology Co ranks #521 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #521 out of 701 companies for Days Payable. This places Genovate Biotechnology Co in the lower half of its industry. The industry median Days Payable is 112.84. Genovate Biotechnology Co's value of 36.37 is 67.8% below this benchmark. Historically, Genovate Biotechnology Co's own Days Payable has ranged from 37.28 to 54.25 over the past decade. While the company's 10-year median is 46.26 vs. the industry median of 112.84, Genovate Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovate Biotechnology Co's current Days Payable of 36.37 is 67.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genovate Biotechnology Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovate Biotechnology Co's current Days Payable is 36.37, which is 21% below median its own 10-year median of 46.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current Days Payable is 36.37, which is 21% below median its 10-year median of 46.26 and 67.8% below the Biotechnology industry median of 112.84. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Days Payable is 36.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20.
GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4130:
Days Payable: 36.37 (21% below median its 10-year median of 46.26)
GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
Industry Position: 67.8% below the Biotechnology median (#521 of 701)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score
Get the complete analysis for ROCO:4130
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
